---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-008556"
form_type: "8-K"
ticker: "SRRK"
cik: "0001727196"
company_name: "Scholar Rock Holding Corp"
filed_at: "2024-05-22T23:59:59+00:00"
generated_at: "2026-06-01T09:47:41.224710+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Scholar Rock initiates Phase 2 EMBRAZE obesity trial; SRK-439 preclinical data shows superiority over anti-ActRII

## Summary
- Phase 2 EMBRAZE proof-of-concept trial initiated for apitegromab in obesity, targeting 100 subjects on GLP-1 RA; primary data expected mid-2025.
- Preclinical head-to-head: SRK-439 at 1 mg/kg preserved lean mass equivalent to anti-ActRII at 20 mg/kg; all doses showed superiority.
- Loan Amendment No. 4 extends interest-only period to May 2025, modifies milestones for $25M additional tranche available through Dec 2024.
- SRK-439 attenuated lean mass loss to 4.2% at 10 mg/kg vs. 14.1% with IgG control + semaglutide in DIO mice.
- Company hosts Investor Day; anticipates IND filing for SRK-439 in 2025 after EMBRAZE results.

## SEC filing metadata
- accession: 0001558370-24-008556
- form_type: 8-K
- ticker: SRRK
- cik: 0001727196
- company_name: Scholar Rock Holding Corp
- filed_at: 2024-05-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1727196/000155837024008556/0001558370-24-008556-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1727196/000155837024008556/srrk-20240517x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-008556
- JSON: https://secwatch.observer/filing/0001558370-24-008556.json
- Plain text: https://secwatch.observer/filing/0001558370-24-008556.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.